Clinical trials: Non-allergic Asthma
Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with…
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05660850
- Testing
- GDC-6599, Mannitol
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- Genentech, Inc.
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Immune Dysfunction in Allergic Asthma
We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.
- Trial name
- NCT00189228
- Testing
- Xolair
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of New Mexico
Asthma, Allergic Asthma
Characterization of the Role of Histamine in Children With Asthma
Asthma, a chronic disease which produces significant morbidity and mortality in children, is a significant health problem to a large segment of society.
- Conditions
- Asthma, Allergic Asthma, Non-allergic Asthma
- Trial name
- NCT01392859
- Testing
- Levocetirizine 0.5 Mg/mL Oral Solution
- Where
- United States
- Volunteers
- 211 people
- Sponsor
- Children's Mercy Hospital Kansas City
Asthma
Effect of Anti-IgE in Non-Allergic Asthma
The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.
- Trial name
- NCT00162773
- Testing
- omalizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Mild, Allergic Asthma
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS
To test the hypothesis that gamma tocopherol (vitamin E) supplement inhibits endotoxin induced airways inflammation in allergic asthmatics
- Trial name
- Vitalps (NCT02104505)
- Testing
- Gamma Tocopherol 700 mg capsules,
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of North Carolina, Chapel Hill
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters